Brendan Classon

Brendan Classon

Company: Parvus Therapeutics

Job title: Executive VP, Research & Development


A nanomedicine approach to treat autoimmune disease leverages a natural differentiation pathway of T regulatory-1 (TR1) cells. 2:30 pm

T-follicular helper (TFH) cells can serve as in vivo precursors of TR1 cells in humans and in mice Complete differentiation of TR1 effector function requires the transcription factor Blimp-1 (Prdm1) Navacims, a pMHC-II nanomedicine platform induce TFH expansion and differentiation to immunomodulatory TR1 cellsRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.